Influence of antiviral treatment in hepatitis C patients on metabolism and fibrosis process
DAA therapy significantly alters metabolic and inflammatory biomarkers in HCV patients, with regimen- and fibrosis stage-specific effects. S/V may provide broader metabolic benefits in advanced disease, while G/P offers stronger anti-inflammatory responses earlier, supporting personalized treatment approaches.
Authors
- Filip M. Szymański (ORCID: https://orcid.org/0000-0002-2638-7894)
- Krzysztof Tomasiewicz (ORCID: https://orcid.org/0000-0001-7868-2708)
- Malwina Jędrysik (ORCID: https://orcid.org/0000-0002-0156-2588)
- Beata Chełstowska (ORCID: https://orcid.org/0000-0002-0671-101X)
- Magdalena Tudrujek-Zdunek
Institutions
- Medical University of Lublin (PL)
- Cardinal Stefan Wyszynski University in Warsaw (PL)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fmed.2026.1729835
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00